Head-To-Head Survey: Miragen Therapeutics (MGEN) versus BG Medicine (BGMD)

BG Medicine (OTCMKTS: BGMD) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for BG Medicine and Miragen Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BG Medicine 0 0 0 0 N/A
Miragen Therapeutics 0 0 3 0 3.00

Miragen Therapeutics has a consensus price target of $24.00, suggesting a potential upside of 210.48%. Given Miragen Therapeutics’ higher possible upside, analysts clearly believe Miragen Therapeutics is more favorable than BG Medicine.

Valuation & Earnings

This table compares BG Medicine and Miragen Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BG Medicine $1.57 million 0.29 -$5.30 million N/A N/A
Miragen Therapeutics $3.34 million 51.63 -$12.67 million ($8.93) -0.87

BG Medicine has higher earnings, but lower revenue than Miragen Therapeutics.

Risk and Volatility

BG Medicine has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Institutional & Insider Ownership

22.6% of Miragen Therapeutics shares are owned by institutional investors. 6.5% of BG Medicine shares are owned by company insiders. Comparatively, 44.4% of Miragen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares BG Medicine and Miragen Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BG Medicine N/A N/A N/A
Miragen Therapeutics -720.38% -80.31% -64.59%

Summary

Miragen Therapeutics beats BG Medicine on 7 of the 11 factors compared between the two stocks.

About BG Medicine

BG Medicine, Inc. (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company’s BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners’ automated platforms. The Company’s CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.

About Miragen Therapeutics

Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company’s MyPRS test provides a whole-genomic expression profile of a patient’s multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.

Receive News & Ratings for BG Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BG Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply